Loading clinical trials...
Loading clinical trials...
An Open Label Phase II Study of Oral Treatment With Sunitinib (SUTENT) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen
Conditions
Interventions
sunitinib
Locations
1
France
Service Oncologie Médicale, Hopital Europeen Georges Pompidou
Paris, France
Start Date
March 1, 2008
Primary Completion Date
April 1, 2011
Completion Date
April 1, 2011
Last Updated
September 18, 2013
NCT07225946
NCT04868604
NCT00756665
NCT05743621
NCT04104776
NCT06242119
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions